Amicus (FOLD) Q2 Revenue Jumps 22%
Amicus Therapeutics (NASDAQ:FOLD), a specialist in rare disease medicines, delivered quarterly results on July 31, 2025 that notably surpassed expectations on both GAAP revenue and non-GAAP earnings. The company reported GAAP revenue of $154.7 million, up from $126.7 million (GAAP) a year earlier and $8.0 million ahead of the $146.7 million analyst target. Non-GAAP earnings per share came in at $0.01, far better than the non-GAAP EPS estimate of –$0.12. The quarter showed solid commercial momentum for the company’s lead therapies, with ongoing expansion of its pipeline and continued global launches. Despite higher operating expenses and a narrowed growth outlook for a key product line, overall performance marked another solid step in Amicus’s growth plan.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Amicus Therapeutics develops and markets treatments for people with rare diseases, focusing on genetic disorders. Its business centers on two key therapies: Galafold, a daily oral pill for Fabry disease, and Pombiliti + Opfolda, an enzyme replacement system for Pompe disease. Both products target lifelong, serious conditions for which there are few treatment options.
Source Fool.com
Amicus Therapeutics Inc. Stock
Amicus Therapeutics Inc. is currently one of the favorites of our community with 11 Buy predictions and no Sell predictions.
With a target price of 16 € there is potential for a 178.26% increase which would mean more than doubling the current price of 5.75 € for Amicus Therapeutics Inc..
